Overview

Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
All
Summary
The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Folic Acid
Paclitaxel
Criteria
Inclusion Criteria:

- Pathologically proven esophageal squamous cell or adenocarcinoma Recurrence or
metastasis Measurable disease (> 1 X 1 cm) by CXR, CT scan or MRI,Age > 18, KPS > 60%
, Cre < 1.5mg/dl, AST/ALT < 3.5 X N, Bil < 2.0mg/dl WBC > 4,000/mm3, ANC > 2,000/ mm3,
Plt > 100,000/mm3

Exclusion Criteria:

- Prior chemo (except as radiosensitizers)Recurrent, treated esophageal lesion only
(except > 2 months)